CoChat

Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype

Open access
Weber, Leslie, Frati, Giacomo, Felix, Tristan, Hardouin, Giulia, Casini, Antonio, Wollenschlaeger, Clara, Meneghini, Vasco, Masson, Cecile, De Cian, Anne, Chalumeau, Anne, Mavilio, Fulvio, Amendola, Mario, Andre-Schmutz, Isabelle, Cereseto, Anna, El Nemer, Wassim, Concordet, Jean-Paul, Giovannangeli, Carine, Cavazzana, Marina, Miccio, Annarita · 2020 · Science Advances

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Editing the fetal γ-globin promoters in hematopoietic stem cells from sickle cell disease patients induces therapeutic γ-globin levels.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.aay9392

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 LRF-binding site disruption induces γ-globin expression in HUDEP-2 cells. (A) Schematic representation of the β-globin locus on chromosome 11, depicting the hypersensitive sites of the locus control region (white boxes) and the HBE1, HBG2, HBG1, HBD, and HBB genes (colored boxes). The sequence of the HBG2 and HBG1 identical promoters (from −210 to −100 nucleotides upstream of the HBG TSS) is shown below. Black arrows indicate HPFH mutations described at HBG1 and/or HBG2 promoters, with the percentage of HbF in heterozygous carriers of HPFH mutations (42). The highest HbF levels were generally observed in individuals carrying SCD (*) or β-thalassemia mutations (**). LRF- and BCL11A-binding sites [as described in (11)] are highlighted by orange and green boxes, respectively. The −114/−102 13-bp HPFH deletion is indicated by an empty box. Red arrows indicate the gRNA cleavage sites. (B to E) Globin expression analyses were performed in mature erythroblasts differentiated from Cas9-GFP+ HUDEP-2 cells. Results are shown as means ± SEM of three to four independent experiments. (B) RT-qPCR quantification of (Gγ + Aγ)- and β-globin transcripts. mRNA levels were expressed as percentage of (γ + β) globins, after normalization to α-globin mRNA levels. (C) Representative flow cytometry plots showing the percentage of HbF+ cells. (D) RP-HPLC analysis of globin chains. β-Like globin expression was normalized to α-globin. Representative RP-HPLC chromatograms are reported together with the expression of γ-globin chains (in brackets). The ratio of α chains to non–α chains was similar between HBG-edited and control samples. (E) ChIP-qPCR analysis of H3K27Ac at HBB and HBG promoters in −197-edited HUDEP-2 cells and control AAVS1–edited samples (day 5 of differentiation, n = 3). ChIP was performed using an antibody against H3K27Ac and the corresponding control immunoglobulin G (IgG). ****P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05 (unpaired t test). SSC, side scatter. (F) ChIP-qPCR analysis of LRF at HBG promoters in −197-edited and control AAVS1–edited K562 cells (n = 2 biologically independent experiments). ChIP was performed using an antibody against LRF. Two different primer pairs were used to amplify the HBG promoters (A and B). KLF1 and DEFB122 served as positive and negative controls, respectively.
Fig. 1 LRF-binding site disruption induces γ-globin expression in HUDEP-2 cells. (A) Schematic representation of the β-globin locus on chromosome 11, depicting the hypersensitive sites of the locus control region (white boxes) and the HBE1, HBG2, HBG1, HBD, and HBB genes (colored boxes). The sequence of the HBG2 and HBG1 identical promoters (from −210 to −100 nucleotides upstream of the HBG TSS) is shown below. Black arrows indicate HPFH mutations described at HBG1 and/or HBG2 promoters, with the percentage of HbF in heterozygous carriers of HPFH mutations (42). The highest HbF levels were generally observed in individuals carrying SCD (*) or β-thalassemia mutations (**). LRF- and BCL11A-binding sites [as described in (11)] are highlighted by orange and green boxes, respectively. The −114/−102 13-bp HPFH deletion is indicated by an empty box. Red arrows indicate the gRNA cleavage sites. (B to E) Globin expression analyses were performed in mature erythroblasts differentiated from Cas9-GFP+ HUDEP-2 cells. Results are shown as means ± SEM of three to four independent experiments. (B) RT-qPCR quantification of (Gγ + Aγ)- and β-globin transcripts. mRNA levels were expressed as percentage of (γ + β) globins, after normalization to α-globin mRNA levels. (C) Representative flow cytometry plots showing the percentage of HbF+ cells. (D) RP-HPLC analysis of globin chains. β-Like globin expression was normalized to α-globin. Representative RP-HPLC chromatograms are reported together with the expression of γ-globin chains (in brackets). The ratio of α chains to non–α chains was similar between HBG-edited and control samples. (E) ChIP-qPCR analysis of H3K27Ac at HBB and HBG promoters in −197-edited HUDEP-2 cells and control AAVS1–edited samples (day 5 of differentiation, n = 3). ChIP was performed using an antibody against H3K27Ac and the corresponding control immunoglobulin G (IgG). ****P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05 (unpaired t test). SSC, side scatter. (F) ChIP-qPCR analysis of LRF at HBG promoters in −197-edited and control AAVS1–edited K562 cells (n = 2 biologically independent experiments). ChIP was performed using an antibody against LRF. Two different primer pairs were used to amplify the HBG promoters (A and B). KLF1 and DEFB122 served as positive and negative controls, respectively.CC BY-NC · PubMed Central
Fig. 2 Efficient editing of HBG promoters in HSPCs. (A) Deep sequencing analysis of genome editing events in mature erythroblasts derived from adult SCD and CB healthy donor HSPCs. The InDel profile was unchanged between SCD and healthy donor cells. Frequencies of substitutions (subst), insertions (ins), and deletions (del) are shown as percentages of total InDels. The proportion of >1-bp deletions associated or not with MH motifs is indicated. The frequency of >1-bp deletions associated with MH motifs was significantly lower for the −196 gRNA compared to the −197 (P ≤ 0.01) and −195 (P ≤ 0.001) gRNAs. Data are expressed as means ± SEM (n = 3 to 4, two to three donors). (B) Genome editing efficiency in BFU-E and CFU-GM progenitors derived from edited SCD HSPCs as evaluated by TIDE. Data are expressed as means ± SEM (n = 2 to 5, two SCD donors). (C) Genome editing in single BFU-E and CFU-GM colonies derived from SCD HSPCs as evaluated by TIDE. We plotted the number of edited HBG promoters. In the −158 sample, the donor did not harbor the −158 SNP. (D) InDel profiles generated by each gRNA as analyzed by deep sequencing. The length of MH motifs associated with specific InDels is indicated. Data are expressed as means ± SEM (n = 3 to 4, two to three donors). (E) Genome editing efficiency in subpopulations of −197- and −196-edited CB-derived HSPCs. Cells were FACS-sorted based on the expression of CD34, CD133, and CD90, and genome editing efficiency was determined in committed (CD34+CD133−), early (CD34+CD133+CD90−), and primitive (CD34+CD133+CD90+) progenitors. We plotted the data of three independent experiments starting from unsorted HSPCs with low, medium, and high genome editing efficiency (three donors).
Fig. 2 Efficient editing of HBG promoters in HSPCs. (A) Deep sequencing analysis of genome editing events in mature erythroblasts derived from adult SCD and CB healthy donor HSPCs. The InDel profile was unchanged between SCD and healthy donor cells. Frequencies of substitutions (subst), insertions (ins), and deletions (del) are shown as percentages of total InDels. The proportion of >1-bp deletions associated or not with MH motifs is indicated. The frequency of >1-bp deletions associated with MH motifs was significantly lower for the −196 gRNA compared to the −197 (P ≤ 0.01) and −195 (P ≤ 0.001) gRNAs. Data are expressed as means ± SEM (n = 3 to 4, two to three donors). (B) Genome editing efficiency in BFU-E and CFU-GM progenitors derived from edited SCD HSPCs as evaluated by TIDE. Data are expressed as means ± SEM (n = 2 to 5, two SCD donors). (C) Genome editing in single BFU-E and CFU-GM colonies derived from SCD HSPCs as evaluated by TIDE. We plotted the number of edited HBG promoters. In the −158 sample, the donor did not harbor the −158 SNP. (D) InDel profiles generated by each gRNA as analyzed by deep sequencing. The length of MH motifs associated with specific InDels is indicated. Data are expressed as means ± SEM (n = 3 to 4, two to three donors). (E) Genome editing efficiency in subpopulations of −197- and −196-edited CB-derived HSPCs. Cells were FACS-sorted based on the expression of CD34, CD133, and CD90, and genome editing efficiency was determined in committed (CD34+CD133−), early (CD34+CD133+CD90−), and primitive (CD34+CD133+CD90+) progenitors. We plotted the data of three independent experiments starting from unsorted HSPCs with low, medium, and high genome editing efficiency (three donors).CC BY-NC · PubMed Central
Fig. 3 γ-Globin reactivation and amelioration of the SCD cell phenotype following disruption of LRF-binding site in SCD HSPCs. (A) (Gγ + Aγ)- and βS-globin transcript levels detected by RT-qPCR in primary mature erythroblasts. Values are expressed as percentage of (γ + βS)-globin mRNAs after normalization to α-globin. (B) Representative flow cytometry plots showing the percentage of HbF+ cells in RBC populations derived from control and HBG-edited SCD HSPCs. (C) RP-HPLC quantification of γ-, βS-, and δ-globin chains. β-Like globin expression was normalized to α-globin. The ratio of α chains to non–α chains was similar between control and HBG-edited samples. Data are expressed as means ± SEM. (D) Quantification of total HbF (HbF + AcHbF), HbS, and HbA2 by CE-HPLC. We plotted the percentage of each Hb type over the total Hb tetramers. (E and F) In vitro sickling assay of RBCs derived from edited SCD HSPCs under hypoxic conditions (0% O2). (E) Representative photomicrographs of RBCs derived from control and HBG-edited SCD HSPCs at 0% O2. Scale bar, 20 μm. (F) Proportion of non-sickled RBCs (0% O2). (A to F) Data are expressed as means ± SEM (n = 3 to 7, two SCD donors). ****P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05 versus AAVS1 sample (unpaired t test).
Fig. 3 γ-Globin reactivation and amelioration of the SCD cell phenotype following disruption of LRF-binding site in SCD HSPCs. (A) (Gγ + Aγ)- and βS-globin transcript levels detected by RT-qPCR in primary mature erythroblasts. Values are expressed as percentage of (γ + βS)-globin mRNAs after normalization to α-globin. (B) Representative flow cytometry plots showing the percentage of HbF+ cells in RBC populations derived from control and HBG-edited SCD HSPCs. (C) RP-HPLC quantification of γ-, βS-, and δ-globin chains. β-Like globin expression was normalized to α-globin. The ratio of α chains to non–α chains was similar between control and HBG-edited samples. Data are expressed as means ± SEM. (D) Quantification of total HbF (HbF + AcHbF), HbS, and HbA2 by CE-HPLC. We plotted the percentage of each Hb type over the total Hb tetramers. (E and F) In vitro sickling assay of RBCs derived from edited SCD HSPCs under hypoxic conditions (0% O2). (E) Representative photomicrographs of RBCs derived from control and HBG-edited SCD HSPCs at 0% O2. Scale bar, 20 μm. (F) Proportion of non-sickled RBCs (0% O2). (A to F) Data are expressed as means ± SEM (n = 3 to 7, two SCD donors). ****P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05 versus AAVS1 sample (unpaired t test).CC BY-NC · PubMed Central
Fig. 4 Editing efficiency in repopulating HSPCs. (A) Engraftment of human cells in NSG mice transplanted with untreated (UT) and edited mobilized healthy donor CD34+ cells (n = 4 mice for each group) 16 weeks after transplantation. Engraftment is represented as percentage of human CD45+ cells in the total murine and human CD45+ cell population, in bone marrow (BM), spleen, thymus, and blood. Values shown are means ± SEM; *P ≤ 0.05 versus untreated [one-way analysis of variance (ANOVA)]. (B) Editing efficiency in the bone marrow– and spleen-derived human CD45+ progeny of repopulating HSPCs, as evaluated by Sanger sequencing and TIDE analysis. The proportion of edited alleles in the input HSPC populations (〇: HSPCs cultured for 6 days in “HSPC medium”; □: BFU-E; △: CFU-GM) is indicated (input). Values shown are means ± SEM. Each data point represents an individual mouse. (C) Genome editing efficiency in the input populations and in bone marrow– and spleen-derived human CD45+ populations edited with the −197, −196, or −115 gRNAs, as evaluated by Sanger sequencing and TIDE analysis. The main events associated with MH-motifs are indicated. Values shown are means ± SEM (n = 4 mice per group). ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05 versus input (unpaired t test).
Fig. 4 Editing efficiency in repopulating HSPCs. (A) Engraftment of human cells in NSG mice transplanted with untreated (UT) and edited mobilized healthy donor CD34+ cells (n = 4 mice for each group) 16 weeks after transplantation. Engraftment is represented as percentage of human CD45+ cells in the total murine and human CD45+ cell population, in bone marrow (BM), spleen, thymus, and blood. Values shown are means ± SEM; *P ≤ 0.05 versus untreated [one-way analysis of variance (ANOVA)]. (B) Editing efficiency in the bone marrow– and spleen-derived human CD45+ progeny of repopulating HSPCs, as evaluated by Sanger sequencing and TIDE analysis. The proportion of edited alleles in the input HSPC populations (〇: HSPCs cultured for 6 days in “HSPC medium”; □: BFU-E; △: CFU-GM) is indicated (input). Values shown are means ± SEM. Each data point represents an individual mouse. (C) Genome editing efficiency in the input populations and in bone marrow– and spleen-derived human CD45+ populations edited with the −197, −196, or −115 gRNAs, as evaluated by Sanger sequencing and TIDE analysis. The main events associated with MH-motifs are indicated. Values shown are means ± SEM (n = 4 mice per group). ***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05 versus input (unpaired t test).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. 10.1016/j.ymthe.2018.10.008 · DOI · Paper page

Cited by

See all 142

Metadata

Authors
Weber, L., Frati, G., Felix, T., Hardouin, G., Casini, A., Wollenschlaeger, C., Meneghini, V., Masson, C., De Cian, A., Chalumeau, A., Mavilio, F., Amendola, M., Andre-Schmutz, I., Cereseto, A., El Nemer, W., Concordet, J.-P., Giovannangeli, C., Cavazzana, M., & Miccio, A.
Affiliations
  • Inserm (FR)
  • Laboratory of chromatin and gene regulation during development, INSERM UMR1163, Paris, France.
  • University of Trento (IT)
  • Paris-Descartes Bioinformatics Platform, Imagine Institute, Paris 75015, France.
  • INSERM U1154, CNRS UMR7196, Museum National d’Histoire Naturelle, Paris, France.
  • University of Modena and Reggio Emilia (IT)
  • Laboratory of Human Lymphohematopoiesis, INSERM UMR1163, Paris, France.
  • Biologie Intégrée du Globule Rouge UMR_S1134, Inserm, Univ. Paris Diderot, Sorbonne Paris Cité, Univ. de la Réunion, Univ. des Antilles, Paris, France.
  • Centre National de la Recherche Scientifique (FR)
  • Hôpital Necker-Enfants Malades (FR)
Corresponding author
  • Weber, Leslie
  • Frati, Giacomo
  • Miccio, Annarita
Venue
Science Advances
Published
2020-02-14
Volume
6
Issue
7
Pages
eaay9392
ISSN
2375-2548 (ISSN-L)
OpenAlex
W3006567544
Cited by
140
References
53
Citations by year
2026: 11 · 2025: 19 · 2024: 20 · 2023: 26 · 2022: 19 · 2021: 30 · 2020: 15
FWCI
11.65
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by-nc)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, cc-by-nc)
  • Institutional Research Information System (Università degli Studi di Trento) (submittedVersion, cc-by-nc)
  • HAL (submittedVersion)
  • HAL (submittedVersion, other-oa)
Funders
  • European Research Council
  • Agence Nationale de la Recherche
  • Genopole
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
sickle cell disease, fetal hemoglobin, CRISPR/Cas9 genome editing, hematopoietic stem and progenitor cells, xenotransplantation, promoter editing
MeSH terms
Gene Editing, Anemia, Sickle Cell, Binding Sites, Fetal Hemoglobin, Humans, Phenotype, beta-Thalassemia, beta-Globins, gamma-Globins, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.